Organogenesis (ORGO) Scheduled to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is set to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Organogenesis has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Organogenesis had a return on equity of 2.11% and a net margin of 1.34%. The firm had revenue of $109.98 million for the quarter, compared to analysts’ expectations of $100.44 million. During the same period last year, the firm earned ($0.02) EPS. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Stock Up 4.4 %

ORGO opened at $2.59 on Wednesday. Organogenesis has a 12 month low of $1.96 and a 12 month high of $4.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.41. The stock has a market cap of $343.36 million, a P/E ratio of 64.77 and a beta of 1.65. The stock’s 50 day moving average price is $2.76 and its 200 day moving average price is $2.93.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital started coverage on Organogenesis in a research report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price on the stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.